Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH.

Leukemia. 2012 Sep;26(9):2103-13. doi: 10.1038/leu.2012.83. Epub 2012 Mar 22. Erratum in: Leukemia. 2014 Apr;28(4):980.

2.

Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia.

Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, Mori Y, Iino T, Yamauchi T, Eto T, Niiro H, Iwasaki H, Takenaka K, Akashi K.

Cancer Cell. 2011 Aug 16;20(2):246-59. doi: 10.1016/j.ccr.2011.06.029.

3.

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA.

Cancer Cell. 2011 Jul 12;20(1):25-38. doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.

4.

Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.

Thome M, Charton JE, Pelzer C, Hailfinger S.

Cold Spring Harb Perspect Biol. 2010 Sep;2(9):a003004. doi: 10.1101/cshperspect.a003004. Epub 2010 Aug 4. Review.

5.

Oncogenic activation of NF-kappaB.

Staudt LM.

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109. doi: 10.1101/cshperspect.a000109. Epub 2010 Apr 21. Review.

6.

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, Penas EM, Dierlamm J, Chan WC, Staudt LM, Thome M.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19946-51. doi: 10.1073/pnas.0907511106. Epub 2009 Nov 6. Erratum in: Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2677.

7.

Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.

Ferch U, Kloo B, Gewies A, Pfänder V, Düwel M, Peschel C, Krappmann D, Ruland J.

J Exp Med. 2009 Oct 26;206(11):2313-20. doi: 10.1084/jem.20091167. Epub 2009 Oct 19. Erratum in: J Exp Med. 2009 Nov 23;206(12):2851.

8.

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC.

Clin Cancer Res. 2009 Sep 1;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113. Epub 2009 Aug 25.

9.

Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.

Li Z, Wang H, Xue L, Shin DM, Roopenian D, Xu W, Qi CF, Sangster MY, Orihuela CJ, Tuomanen E, Rehg JE, Cui X, Zhang Q, Morse HC 3rd, Morris SW.

Blood. 2009 Nov 5;114(19):4158-68. doi: 10.1182/blood-2008-12-192583. Epub 2009 Aug 20.

10.

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.

Blood. 2009 Jun 11;113(24):6069-76. doi: 10.1182/blood-2009-01-199679. Epub 2009 Apr 20.

11.

Cancer induction by restriction of oncogene expression to the stem cell compartment.

Pérez-Caro M, Cobaleda C, González-Herrero I, Vicente-Dueñas C, Bermejo-Rodríguez C, Sánchez-Beato M, Orfao A, Pintado B, Flores T, Sánchez-Martín M, Jiménez R, Piris MA, Sánchez-García I.

EMBO J. 2009 Jan 7;28(1):8-20. doi: 10.1038/emboj.2008.253. Epub 2008 Nov 27.

12.

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. doi: 10.1073/pnas.0804295105. Epub 2008 Sep 2.

13.

The proteolytic activity of the paracaspase MALT1 is key in T cell activation.

Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, Gaide O, Guzzardi M, Iancu EM, Rufer N, Fasel N, Thome M.

Nat Immunol. 2008 Mar;9(3):272-81. doi: 10.1038/ni1568. Epub 2008 Feb 10.

PMID:
18264101
14.

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.

Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R.

Nat Immunol. 2008 Mar;9(3):263-71. doi: 10.1038/ni1561. Epub 2008 Jan 27.

PMID:
18223652
15.

The pathogenesis of MALT lymphomas: where do we stand?

Sagaert X, De Wolf-Peeters C, Noels H, Baens M.

Leukemia. 2007 Mar;21(3):389-96. Epub 2007 Jan 18. Review.

PMID:
17230229
16.

Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.

Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V, Billiau AD, De Wolf-Peeters C, Marynen P.

Cancer Res. 2006 May 15;66(10):5270-7.

17.

Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.

Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C.

J Clin Oncol. 2006 Jun 1;24(16):2490-7. Epub 2006 Apr 24.

18.

Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma.

Farinha P, Gascoyne RD.

J Clin Oncol. 2005 Sep 10;23(26):6370-8. Review.

PMID:
16155022
19.

XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.

Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM.

Immunity. 2004 Jul;21(1):81-93.

20.

MALT lymphoma: from morphology to molecules.

Isaacson PG, Du MQ.

Nat Rev Cancer. 2004 Aug;4(8):644-53. Review. No abstract available.

PMID:
15286744
Items per page

Supplemental Content

Write to the Help Desk